TrialLung2021
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Alyn H Morice et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this paperpooled ittrialcites it